DUBLIN--(BUSINESS WIRE)--The "Genital Herpes - Market Insights, Epidemiology and Market Forecast - 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
The market of Genital Herpes in 7MM was found to be USD 883 million in 2016.
Genital Herpes- Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Genital Herpes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Genital Herpes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The current therapeutic market is dominated by the use of anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir. Since these drugs have gone off patent the therapeutic market is flooded with their generic versions. Detailed chapter for upcoming therapies like Pritelivir (AiCuris.), two therapeutic vaccines VCL-HBOL (Vical) and GEN-003 (Genocea Biosciences) and M5210B (Maruho) have been covered in the report.
Key Topics Covered:
1. Key Insights
2. Genital Herpes Market Overview at a Glance
3. Disease Background and Overview: Genital Herpes
4. Epidemiology and Patient Population
5. Country Wise-Epidemiology of Genital Herpes
6. Current Treatment and Medical Practices
7. Unmet Needs
8. Marketed drugs
9. Emerging Drugs
10. Genital Herpes: 7 Major Market Analysis
11. Market Outlook by Country
12. Market Drivers
13. Market Barriers
- Genocea Biosciences
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/glm66n/genital_herpes?w=4